155 related articles for article (PubMed ID: 17230512)
1. Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy.
Berg A; Berner A; Lilleby W; Bruland ØS; Fosså SD; Nesland JM; Kvalheim G
Int J Cancer; 2007 Apr; 120(8):1603-9. PubMed ID: 17230512
[TBL] [Abstract][Full Text] [Related]
2. Disseminated tumor cells and their prognostic significance in nonmetastatic prostate cancer patients.
Lilleby W; Stensvold A; Mills IG; Nesland JM
Int J Cancer; 2013 Jul; 133(1):149-55. PubMed ID: 23280694
[TBL] [Abstract][Full Text] [Related]
3. Disseminated tumor cells in bone marrow following definitive radiotherapy for intermediate or high-risk prostate cancer.
Berg A; Bruland ØS; Fosså SD; Nesland JM; Berner A; Schirmer C; Lilleby W
Prostate; 2008 Nov; 68(15):1607-14. PubMed ID: 18655095
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment.
Köllermann J; Weikert S; Schostak M; Kempkensteffen C; Kleinschmidt K; Rau T; Pantel K
J Clin Oncol; 2008 Oct; 26(30):4928-33. PubMed ID: 18794550
[TBL] [Abstract][Full Text] [Related]
5. The prognostic impact of cytokeratin-positive cells in bone marrow of patients with localized prostate cancer.
Lilleby W; Nesland JM; Fosså SD; Torlakovic G; Waehre H; Kvalheim G
Int J Cancer; 2003 Jan; 103(1):91-6. PubMed ID: 12455058
[TBL] [Abstract][Full Text] [Related]
6. External beam radiotherapy for clinically node-negative, localized hormone-refractory prostate cancer: impact of pretreatment PSA value on radiotherapeutic outcomes.
Akimoto T; Kitamoto Y; Saito J; Harashima K; Nakano T; Ito K; Yamamoto T; Kurokawa K; Yamanaka H; Takahashi M; Mitsuhashi N; Niibe H
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):372-9. PubMed ID: 15145150
[TBL] [Abstract][Full Text] [Related]
7. Urokinase-plasminogen-activator receptor expression in disseminated tumour cells in the bone marrow and peripheral blood of patients with clinically localized prostate cancer.
Thomas C; Wiesner C; Melchior SW; Schmidt F; Gillitzer R; Thüroff JW; Pfitzenmaier J
BJU Int; 2009 Jul; 104(1):29-34. PubMed ID: 19154451
[TBL] [Abstract][Full Text] [Related]
8. Presence of disseminated tumor cells in bone marrow correlates with tumor stage and nodal involvement in cervical cancer patients.
Fehm T; Banys M; Rack B; Jäger B; Hartkopf A; Taran FA; Janni W
Int J Cancer; 2014 Feb; 134(4):925-31. PubMed ID: 23921989
[TBL] [Abstract][Full Text] [Related]
9. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
Vargas C; Martínez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J
Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040
[TBL] [Abstract][Full Text] [Related]
10. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
11. Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer.
Wiedswang G; Borgen E; Kåresen R; Kvalheim G; Nesland JM; Qvist H; Schlichting E; Sauer T; Janbu J; Harbitz T; Naume B
J Clin Oncol; 2003 Sep; 21(18):3469-78. PubMed ID: 12972522
[TBL] [Abstract][Full Text] [Related]
12. Impact of percent positive random biopsies on biochemical outcome in prostate cancer patients treated with external beam radiotherapy with or without androgen deprivation.
Igdem S; Abacioglu U; Cetin I; Alco G; Akgun Z; Sengoz M; Bekiroglu N; Turkan S; Okkan S
J BUON; 2009; 14(4):629-34. PubMed ID: 20148454
[TBL] [Abstract][Full Text] [Related]
13. Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era?
Castle KO; Hoffman KE; Levy LB; Lee AK; Choi S; Nguyen QN; Frank SJ; Pugh TJ; McGuire SE; Kuban DA
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):693-9. PubMed ID: 22836052
[TBL] [Abstract][Full Text] [Related]
14. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
15. Significance of apoptotic and non-apoptotic disseminated tumor cells in the bone marrow of patients with clinically localized prostate cancer.
Todenhöfer T; Hennenlotter J; Faber F; Wallwiener D; Schilling D; Kühs U; Aufderklamm S; Bier S; Mischinger J; Gakis G; Fehm T; Stenzl A; Schwentner C
Prostate; 2015 May; 75(6):637-45. PubMed ID: 25586166
[TBL] [Abstract][Full Text] [Related]
16. [Detection of disseminated carcinoma cells in bone marrow and peripheral blood in primary breast cancer with RT/PCR of parathyroid hormone-related protein (PTHrP)].
Liersch T; Gatzemeier W; Scharnberg P; Jürgens B; Wörmann B; Becker H; Rauschecker HF; Hiddemann W; Wulf GG
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):277-80. PubMed ID: 14518259
[TBL] [Abstract][Full Text] [Related]
17. Redefining micrometastasis in prostate cancer - a comparison of circulating prostate cells, bone marrow disseminated tumor cells and micrometastasis: Implications in determining local or systemic treatment for biochemical failure after radical prostatectomy.
Murray NP; Reyes E; Tapia P; Badinez L; Orellana N; Fuentealba C; Olivares R; Porcell J; Dueñas R
Int J Mol Med; 2012 Oct; 30(4):896-904. PubMed ID: 22825050
[TBL] [Abstract][Full Text] [Related]
18. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis.
Ray ME; Thames HD; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Shipley WU; Zelefsky MJ; Zietman AL; Kuban DA
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1140-50. PubMed ID: 16198506
[TBL] [Abstract][Full Text] [Related]
19. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
Crook J; Ludgate C; Malone S; Lim J; Perry G; Eapen L; Bowen J; Robertson S; Lockwood G
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):15-23. PubMed ID: 15337535
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcomes after high-dose postprostatectomy salvage radiation treatment.
Goenka A; Magsanoc JM; Pei X; Schechter M; Kollmeier M; Cox B; Scardino PT; Eastham JA; Zelefsky MJ
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):112-8. PubMed ID: 22300563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
